News

New EU Research Project BEAMER Seeks to Improve Patient Adherence to Prescribed Treatments

Published on: 30/11/2021

New EU Research Project BEAMER Seeks to Improve Patient Adherence to Prescribed Treatments
Innovative Medicines Initiative (IMI), Patients

An international consortium will investigate factors affecting patient treatment adherence and develop a model to assess and understand patient needs, with the goal to provide better patient support, improve outcomes and promote further adherence.

Today, the Innovative Medicines Initiative (IMI) announced the launch of a promising project that seeks to improve patient treatment adherence, the lack of which (non-adherence) is associated with negative patient outcomes and significant costs. 

Led by Pfizer, co-led by Merck KGaA (Darmstadt, Germany) and managed by the University of Porto, the five-year project – “BEhavioral and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe (BEAMER)” – brings together 28 European partners from academia, civil society and industry to jointly address this goal.

Patient non-adherence to prescribed treatment poses a formidable health challenge. It affects patient health outcomes significantly, contributing to 200,000 premature deaths in the EU annually, and places a heavy economic burden on the healthcare system, leading to an estimated 125B euros in avoidable hospitalisations, emergency care and adult outpatient visits each year. Despite existing research on disease-specific medication adherence, there are few broad insights regarding how to improve adherence across healthcare. To address this, BEAMER aims to acquire a comprehensive understanding of the factors that influence patient adherence, irrespective of the therapeutic area, and enable stakeholders to design effective solutions that could promote broad and consistent impact within a real-world context.

To achieve these objectives, the project will create a generalised model of the significant factors affecting non-adherent behaviour, grounded in behavioural theory. This will allow the project team to define the problem of non-adherence and provide guidance for healthcare stakeholders to develop and implement cost-effective tools and solutions that directly target patient needs, potentially contributing to enhanced patient outcomes and reduced health system costs. Although disease-agnostic,  the model is intended to be tailorable with disease-specific inputs to increase its prediction power and optimise patient support strategies. This degree of flexibility would then enable the model to be widely applicable and responsive to ongoing changes in various populations. 

It [patient non-adherence to prescribed treatment] affects patient health outcomes significantly, contributing to 200,000 premature deaths in the EU annually … and leading to an estimated 125B euros in avoidable hospitalisations, emergency care and adult outpatient visits each year.

“Adherence to therapy is a public health problem, as 50% of patients don’t take their medication as prescribed. This can have a significant impact on their quality of life and health outcomes (including leading to premature death), in addition to increasing health care costs,” says Elísio Costa, BEAMER Project Coordinator and Director of the Competence Centre on Active and Healthy Ageing (Porto4Ageing) at the University of Porto. “To overcome this challenge, we need to better understand the underlying factors behind non-adherence and to work closely with patients and healthcare professionals, who stand to be the main beneficiaries of BEAMER’s potential solution.”

“We are incredibly excited about the potential of BEAMER to improve treatment adherence among patients with many different conditions, from all walks of life,” added Claire Everitt, BEAMER industry Project Lead and Engineering Team Lead at Pfizer. “The positive impacts of successful drug development and diagnosis are greatly reduced if patients aren’t following their prescribed treatment regime. We hope this project will provide the tools to help industry, doctors and healthcare systems improve treatment adherence rates by identifying and addressing patient needs.”


NEWS​

Related News

InnoHSupport Open Calls

11 Feb 2025
Welcome to the InnoHSupport Open Calls!

Healthcare AI Solutions

6 Feb 2025
The UK government has launched a £150 million procurement drive for artificial intelligence solutions that can be used by the NHS in areas like medica...

Women Entrepreneurship Bootcamp

6 Feb 2025
Welcome to EIT Health Women Entrepreneurship Bootcamp – a customised experience crafted exclusively for you.  

MedTech Bootcamp

6 Feb 2025
EIT Health’s MedTech Bootcamp has been exclusively crafted for trailblazers like you to help you get a clear and valid proof of concept for your idea.

Empowering AI Innovations to Transform Lives: GSMA Launches New Innovation Fund for Startups

6 Feb 2025
The GSMA Innovation Fund is offering grants of up to £250,000 and tailored venture-building support for enterprises using AI and emerging technologies...

Co-Creating the Future of Clinical Data: Join Digital Health Nation Challenge

5 Feb 2025
Join the “Improving clinical data capture for better healthcare outcomes” open innovation call, 5 Feb - 21 March, 2025, to explore the challenge of in...

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *